Kei Iimori

Dr. Kei Iimori

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MKMunenori Kawai
Munenori Kawai
AFAkihisa Fukuda
Akihisa Fukuda
MIMunehiro Ikeda
Munehiro Ikeda
KIKei Iimori
Kei Iimori
KMKenta Mizukoshi
Kenta Mizukoshi
HSHiroshi Seno
Hiroshi Seno
Mutations in Polybromo 1 ( PBRM1 ), a subunit of the switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex, are frequently observed in several cancers, including pancreatic ductal adenocarcinoma (PDAC). In this study, we demonstrated that pancreas-specific loss of Pbrm1 in mice harboring Kras mutations and Trp53 deletions accelerated the development of poorly differentiated PDAC, epithelial-mesenchymal transition (EMT), and metastasis, resulting in worsened prognosis. Pbrm1 loss in preexisting PDAC shifted the tumor grade from a well- to a poorly differentiated state and elevated vimentin expression. Pbrm1 -null PDAC exhibited downregulation of apical junction genes and upregulation of EMT pathway genes, including the vimentin and squamous molecular subtype signature genes. Mechanistically, PBRM1 bound to the vimentin gene promoter and directly downregulated its expression. Furthermore, suppression of vimentin in Pbrm1 -null PDAC cells reversed the dedifferentiation phenotype and reduced EMT and metastasis. Consistently, reduced PBRM1 expression correlated with high vimentin expression, poorly differentiated histology, a high recurrence rate, and reduced overall survival in human PDACs. Additionally, PDAC with PBRM1 deletion was associated with the aggressive squamous molecular subtype. Our data established PBRM1 as a tumor suppressor that controls tumor grade and metastasis of PDAC by regulating vimentin expression.

6 September 2024 in Pancreatology
Verified
Journal Article
Open access
MSMakoto Sono
Makoto Sono
KIKei Iimori
Kei Iimori
MNMunemasa Nagao
Munemasa Nagao
SOSatoshi Ogawa
Satoshi Ogawa
TMTakahisa Maruno
Takahisa Maruno
HSHiroshi Seno
Hiroshi Seno
The incidence of pancreatic cancer is on the rise, and its prognosis remains poor. Recent reports have established a link between the gut and oral microbiome and pancreatic cancer. However, the intricacies of this association within the Japanese population remain unclear. In this study, we investigated the gut and oral microbiomes of Japanese patients with pancreatic cancer, comparing them with those of healthy individuals. We recruited 30 patients with untreated pancreatic cancer and 18 healthy controls at Kyoto University Hospital (2018-2022). We performed a comprehensive 16S rRNA gene sequencing to analyze their gut and oral microbiomes. Analysis revealed that the diversity of the gut and oral microbiomes of patients with pancreatic cancer was reduced compared to that of the healthy controls. Specifically, we observed an increase in the genus Streptococcus in both the gut and oral microbiomes and a significant decrease in several butyrate-producing bacteria in fecal samples. Moreover, bacteria such as Streptococcus mitis and Holdemanella biformis were present in pancreatic cancer tissues, suggesting that they might influence the carcinogenesis and progression of pancreatic cancer. The gut and oral microbiome differed between patients with pancreatic cancer and healthy controls, with a notable decrease in butyrate-producing bacteria in the gut microbiome of the patients. This suggests that there may be a distinct microbial signature associated with pancreatic cancer in the Japanese population. Further studies are required to elucidate the microbiome's causal role in this cancer and help develop prognostic markers or targeted therapies.

23 September 2025 in Cellular and Molecular Gastroenterology and Hepatology
Verified
Journal Article
Open access
KIKei Iimori
Kei Iimori
AFAkihisa Fukuda
Akihisa Fukuda
MNMunemasa Nagao
Munemasa Nagao
SMSho Matsuyama
Sho Matsuyama
MIMunehiro Ikeda
Munehiro Ikeda
HSHiroshi Seno
Hiroshi Seno
Intraductal tubulopapillary neoplasm (ITPN) is a rare, high-grade tumor of the pancreatic duct, characterized by distinct molecular features including frequent alterations in the components of switch/sucrose nonfermenting (SWI/SNF) chromatin remodeling complex and PI3K/AKT pathways. This study aimed to investigate the functional role of BRG1, a key SWI/SNF component, in pancreatic ductal cells, particularly in the context of PI3K/AKT pathway activation. We generated conditional knockout mice by crossing Hnf1b-CreERT2, Brg1flox, and Ptenflox strains. Pancreatic organoids were used for subcutaneous xenografts in NOD/SCID mice. Twelve human ITPN specimens were analysed by immunohistochemistry. In the context of PI3K/AKT pathway activation, Brg1 deletion in pancreatic ductal cells led to the development of ITPN accompanied by invasive carcinoma components. An upregulation of the Yes-associated protein 1/transcriptional coactivator with the PDZ-binding motif (YAP/TAZ) pathway was observed in mutant pancreatic ductal cells. In the xenograft model, pancreatic tumour organoids progressed into invasive pancreatic ductal adenocarcinoma (PDAC) with high TAZ expression, indicating sustained YAP/TAZ pathway activation. Furthermore, administration of verteporfin, a YAP/TAZ pathway inhibitor, reduced tumour formation and partially reversed the dedifferentiation of pancreatic ductal cells. Consistent with the mouse data, analysis of 12 human ITPN specimens showed frequent downregulation of SWI/SNF components, with a significant inverse correlation between BRG1 and TAZ expression. Simultaneous loss of Brg1 and Pten in pancreatic ductal cells results in ITPN formation via the activation of the YAP/TAZ pathway in the mouse model. The YAP/TAZ pathway is a key driver of ITPN formation and is a potential therapeutic target for ITPN and ITPN-derived PDAC.

7 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
HKHirotaka Kashima
Hirotaka Kashima
MKMunenori Kawai
Munenori Kawai
KIKei Iimori
Kei Iimori
MNMunemasa Nagao
Munemasa Nagao
TMTakamitsu J Morikawa
Takamitsu J Morikawa
HSHiroshi Seno
Hiroshi Seno
Backgrounds and Aim: Pancreatic cancer is frequently diagnosed at advanced stages, highlighting the need for biomarkers that are capable of detecting early-stage disease in asymptomatic individuals. Recently, apolipoprotein A2 isoforms (ApoA2-ATQ/AT) have been reported as a new blood biomarker for pancreatic cancer. We recently developed diagnostic models based on 100 highly expressed serum microRNAs (miRNAs) combined with CA19-9; these models achieved high accuracy in terms of distinguishing individuals with pancreatic cancer from healthy individuals. This study aimed to compare the diagnostic performance of these miRNA-based models with that of the ApoA2-ATQ/AT biomarker. Methods: Comprehensive sequencing of serum miRNAs was conducted using samples from 120 pancreatic cancer patients recruited across 14 hospitals, along with 93 healthy controls without cancer. Serum CA19-9 levels, miRNA index values, miRNA+CA19-9 index values, and ApoA2 index values were assessed. miRNA-based indices were derived from classification models built on an automated machine-learning platform. Results: The miRNA model (AUC 0.94; 95% CI 0.91–0.97) and the miRNA+CA19-9 model (AUC 0.99; 95% CI 0.98–1.00) outperformed ApoA2 (AUC 0.89; 95% CI 0.84–0.93) in terms of distinguishing individuals with pancreatic cancer from healthy controls across all stages. In early-stage disease (stages 0–I and 0–II), both miRNA-based models also demonstrated superior performance. Strong negative correlations were observed between the ApoA2 index and both the miRNA model index (r = −0.62) and the miRNA+CA19-9 index (r = −0.63). Conclusions: These findings suggest that miRNA-based diagnostic models, particularly when combined with CA19-9, could serve as powerful tools for the early detection of pancreatic cancer.

17 February 2026 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MKMunenori Kawai
Munenori Kawai
AFAkihisa Fukuda
Akihisa Fukuda
MIMunehiro Ikeda
Munehiro Ikeda
KIKei Iimori
Kei Iimori
KMKenta Mizukoshi
Kenta Mizukoshi
HSHiroshi Seno
Hiroshi Seno